



Universiteit
Leiden
The Netherlands

Immunotherapy and beta-cell replacement in type I diabetes mellitus

Linde, P. van de

Citation

Linde, P. van de. (2009, December 16). *Immunotherapy and beta-cell replacement in type I diabetes mellitus*. Retrieved from <https://hdl.handle.net/1887/14521>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/14521>

Note: To cite this publication please use the final published version (if applicable).

**IMMUNOTHERAPY AND BETA-CELL REPLACEMENT
IN TYPE I DIABETES MELLITUS**

Pieter van de Linde

IMMUNOTHERAPY AND BETA-CELL REPLACEMENT IN TYPE I DIABETES MELLITUS

PROEFSCHRIFT

ter verkrijging van
de graad Doctor aan de Universiteit Leiden,
op gezag van de Rector Magnificus prof. mr. P.F. van der Heijden,
volgens besluit van het College van Promoties
te verdedigen op woensdag 16 december 2009
klokke 16:15 uur

door

Pieter van de Linde

geboren te Rotterdam
in 1974.

PROMOTIE COMMISSIE

Promotoren: prof. dr. O.T. Terpstra
 prof. dr. B.O. Roep
 prof. dr. J.W. de Fijter

Overige leden: prof. dr. J.H. van Bockel
 prof. dr. J.A. Romijn
 prof. dr. R. van Schilfgaarde (Universitair Medisch Centrum Groningen)
 dr. A.F.M. Schaapherder

CONTENTS

Chapter 1	General introduction and outline of the thesis	7
	<p>In part published as T-Cell Assays to Determine Disease Activity and Clinical Efficacy of Immune Therapy in Type 1 Diabetes.</p> <p>P. van de Linde and B. O. Roep.</p> <p><i>American Journal of Therapeutics, 2005 (12), 573-579.</i></p>	
Chapter 2	Mechanisms of antibody immunotherapy on clonal islet reactive T-cells.	29
	<p>P. van de Linde, O.M.H Tysma, J.P. Medema, G. Hale, H. Waldmann , D.L. Roelen, B.O. Roep.</p> <p><i>Human Immunology, 2006 (67), p264-273.</i></p>	
Chapter 3	Single high dose ATG-Fresenius equally reduces acute rejection episodes, but may be preferable to five doses daclizumab in pre-transplant GAD-autoantibody seropositive Simultaneous Pancreas and Kidney Transplant recipients.	47
	<p>P. van de Linde, J Ringers, P. J. M. van der Boog , M. J. K. Mallat, E. Bonifacio, B. O. Roep, J. W. de Fijter.</p> <p><i>Submitted.</i></p>	
Chapter 4	Selective unresponsiveness to beta cell autoantigens after induction immunosuppression in pancreas transplantation with anti-IL2 receptor antibody versus anti-thymocyte globulin.	63
	<p>P. van de Linde, P. J.M. vd Boog, O. M.H. Tysma, J. F. Elliott, D. L. Roelen, F. H.J. Claas, J. W. de Fijter and B.O. Roep.</p> <p><i>Clinical Experimental Immunology, 2007 (149), p56-62.</i></p>	

Chapter 5	Alloreactivity against repeated HLA mismatches of sequential islet grafts transplanted in non-uremic type 1 diabetes patients.	77
	C. A. van Kampen, P. van de Linde, G. Duinkerken, J. J. van Schip, D. L. Roelen, B. Keymeulen, D. I. G. Pipeleers, F. H. J. Claas, B. O. Roep. <i>Transplantation 2005 (80), p118-126.</i>	
Chapter 6	Pancreas Transplantation: advantages of both enteric and bladder drainage combined in a two-step approach.	95
	P. van de Linde, P. J. M. van der Boog, A. G. Baranski, J. W. de Fijter, J. Ringers, A. F. M. Schaapherder. <i>Clinical Transplantation 2006 (20), p253-257.</i>	
Chapter 7	General discussion, Summary and Nederlandse samenvatting	105
Chapter 8	Acknowledgements, Curriculum Vitae and List of publications	121